← Back to Search

Sclerosing Agent

23.4% Hypertonic saline for Hidradenitis Suppurativa

Phase 2

Waitlist Available

Led By Maria Palli, MD

Research Sponsored by Beth Israel Deaconess Medical Center

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and week 8

Awards & highlights

Study Summary

This trial looks at whether a 23.4% saline solution can help improve symptoms in adults with hidradenitis suppurativa.

Eligible Conditions

Hidradenitis Suppurativa

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline to visit 8

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline to visit 8

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline to visit 8 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

HS Physician Local Improvement assessment

Secondary outcome measures

Dermatology Life Quality Index

HS Patient Local Improvement assessment

Length of fistula

+2 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Hypertonic SalineExperimental Treatment1 Intervention

23.4% Hypertonic Saline injection(s) with a maximum of 0.4cc per treatment. If necessary every two weeks, with a maximum of three treatments.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

23.4% Hypertonic saline

2016

Completed Phase 2

~30

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Beth Israel Deaconess Medical CenterLead Sponsor

836 Previous Clinical Trials

13,010,209 Total Patients Enrolled

1 Trials studying Hidradenitis Suppurativa

30 Patients Enrolled for Hidradenitis Suppurativa

Maria Palli, MDPrincipal InvestigatorMassachusetts General Hospital

Martina Porter, MDPrincipal InvestigatorBeth Israel Deaconess Medical Center

1 Previous Clinical Trials

20 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the frequency with which 23.4% Hypertonic saline has been used in other research projects?

"As of right now, there are 108 clinical trials underway for 23.4% Hypertonic saline. 30 of those active studies are in Phase 3. Although the many trials for 23.4% Hypertonic saline are based in Philadelphia, Pennsylvania, there are 373 locations running trials for this treatment."

Answered by AI

What is the maximum safe dosage of 23.4% Hypertonic saline for patients?

"We believe that 23.4% Hypertonic saline is safe based on its Phase 3 clinical trial status. There is some efficacy data as well as multiple rounds of safety data supporting our claim."

Answered by AI

How many individuals are under treatment in this clinical trial?

"That is correct. The website clinicaltrials.gov has the most recent information about this trial, which was first posted on 8/1/2016 and was last edited on 11/2/2021. They are looking for 20 individuals to participate at 1 site."

Answered by AI

What is 23.4% Hypertonic saline commonly used to treat?

"23.4% Hypertonic saline is not only effective for the treatment of diarrhea, but can also be used to mitigate conditions such as inflammation of the nasal mucosa, general surgery, and corneal edema."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa

Martina Porter 2016. "Effect of Sclerotherapy on Fistulas and Sinus Tracts in Hidradenitis Suppurativa". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02805595.